Physician profile
Divya Muthappa
NPI 1689803124
$8,390.16
in general payments reported to CMS, 2019-2025
45 companies · $58.85 in 2025
The $58.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $1,694 · 2021: $2,256 · 2022: $2,053 · 2023: $325 · 2024: $322 · 2025: $58.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,154.00 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $879.05 | 2019-2025 | |
| Lilly USA, LLC | $720.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $553.77 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $545.83 | 2019-2024 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $377.53 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $358.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $296.57 | 2019-2021 | |
| Pfizer INC. | $294.01 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $258.12 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $256.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $230.06 | 2019-2022 | |
| Amarin Pharma, INC. | $217.02 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.31 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Muthappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.